Hypercoagulability and hyperfibrinolysis in patients with melanoma

B. Bottasso, D. Mari, R. Coppola, N. Santoro, M. Vaglini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to evaluate whether or not, using sensitive analytical methods for the measurement of coagulation and fibrinolysis enzyme activity, there was a hypercoagulable state in patients with melanoma, and whether differences existed between those with or without metastases. Seventy-one patients were studied, 45 with localized tumors (stages Ia and Ib) and 26 with metastases (stages II-IV). Plasma level of activated factor VII, prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, plasmin-antiplasmin complex and D-dimer were much higher in the whole group of 71 patients than in 45 controls with benign nevi. However, when melanoma patients with or without metastases were compared, there were smaller differences, with only thrombin-antithrombin complex, plasmin-antiplasmin and D-dimer significantly higher in metastatic melanoma. These results indicate that in patients carrying a tumor endowed with high procoagulant activity in vitro, there is a laboratory picture of hypercoagulability with secondary hyperfibrinolysis in vivo. However, differences between patients with localized and metastatic tumors for markers of hypercoagulability are not striking, in spite of the fact that metastatic cells support greater coagulant activity than primary cells in vitro.

Original languageEnglish
Pages (from-to)345-352
Number of pages8
JournalThrombosis Research
Volume81
Issue number3
DOIs
Publication statusPublished - Feb 1 1996

Fingerprint

Thrombophilia
Melanoma
Antifibrinolytic Agents
Fibrinolysin
Neoplasm Metastasis
Fibrinopeptide A
Factor VIIa
Coagulants
Nevus
Fibrinolysis
Tumor Biomarkers
Neoplasms
Enzymes

Keywords

  • activated factor VII
  • hypercoagulability
  • melanoma

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Hypercoagulability and hyperfibrinolysis in patients with melanoma. / Bottasso, B.; Mari, D.; Coppola, R.; Santoro, N.; Vaglini, M.; Mannucci, Pier Mannuccio.

In: Thrombosis Research, Vol. 81, No. 3, 01.02.1996, p. 345-352.

Research output: Contribution to journalArticle

Bottasso, B, Mari, D, Coppola, R, Santoro, N, Vaglini, M & Mannucci, PM 1996, 'Hypercoagulability and hyperfibrinolysis in patients with melanoma', Thrombosis Research, vol. 81, no. 3, pp. 345-352. https://doi.org/10.1016/0049-3848(96)00006-0
Bottasso, B. ; Mari, D. ; Coppola, R. ; Santoro, N. ; Vaglini, M. ; Mannucci, Pier Mannuccio. / Hypercoagulability and hyperfibrinolysis in patients with melanoma. In: Thrombosis Research. 1996 ; Vol. 81, No. 3. pp. 345-352.
@article{b476248ce5644adba64fc193c46cf8ab,
title = "Hypercoagulability and hyperfibrinolysis in patients with melanoma",
abstract = "The purpose of this study was to evaluate whether or not, using sensitive analytical methods for the measurement of coagulation and fibrinolysis enzyme activity, there was a hypercoagulable state in patients with melanoma, and whether differences existed between those with or without metastases. Seventy-one patients were studied, 45 with localized tumors (stages Ia and Ib) and 26 with metastases (stages II-IV). Plasma level of activated factor VII, prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, plasmin-antiplasmin complex and D-dimer were much higher in the whole group of 71 patients than in 45 controls with benign nevi. However, when melanoma patients with or without metastases were compared, there were smaller differences, with only thrombin-antithrombin complex, plasmin-antiplasmin and D-dimer significantly higher in metastatic melanoma. These results indicate that in patients carrying a tumor endowed with high procoagulant activity in vitro, there is a laboratory picture of hypercoagulability with secondary hyperfibrinolysis in vivo. However, differences between patients with localized and metastatic tumors for markers of hypercoagulability are not striking, in spite of the fact that metastatic cells support greater coagulant activity than primary cells in vitro.",
keywords = "activated factor VII, hypercoagulability, melanoma",
author = "B. Bottasso and D. Mari and R. Coppola and N. Santoro and M. Vaglini and Mannucci, {Pier Mannuccio}",
year = "1996",
month = "2",
day = "1",
doi = "10.1016/0049-3848(96)00006-0",
language = "English",
volume = "81",
pages = "345--352",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Hypercoagulability and hyperfibrinolysis in patients with melanoma

AU - Bottasso, B.

AU - Mari, D.

AU - Coppola, R.

AU - Santoro, N.

AU - Vaglini, M.

AU - Mannucci, Pier Mannuccio

PY - 1996/2/1

Y1 - 1996/2/1

N2 - The purpose of this study was to evaluate whether or not, using sensitive analytical methods for the measurement of coagulation and fibrinolysis enzyme activity, there was a hypercoagulable state in patients with melanoma, and whether differences existed between those with or without metastases. Seventy-one patients were studied, 45 with localized tumors (stages Ia and Ib) and 26 with metastases (stages II-IV). Plasma level of activated factor VII, prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, plasmin-antiplasmin complex and D-dimer were much higher in the whole group of 71 patients than in 45 controls with benign nevi. However, when melanoma patients with or without metastases were compared, there were smaller differences, with only thrombin-antithrombin complex, plasmin-antiplasmin and D-dimer significantly higher in metastatic melanoma. These results indicate that in patients carrying a tumor endowed with high procoagulant activity in vitro, there is a laboratory picture of hypercoagulability with secondary hyperfibrinolysis in vivo. However, differences between patients with localized and metastatic tumors for markers of hypercoagulability are not striking, in spite of the fact that metastatic cells support greater coagulant activity than primary cells in vitro.

AB - The purpose of this study was to evaluate whether or not, using sensitive analytical methods for the measurement of coagulation and fibrinolysis enzyme activity, there was a hypercoagulable state in patients with melanoma, and whether differences existed between those with or without metastases. Seventy-one patients were studied, 45 with localized tumors (stages Ia and Ib) and 26 with metastases (stages II-IV). Plasma level of activated factor VII, prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, plasmin-antiplasmin complex and D-dimer were much higher in the whole group of 71 patients than in 45 controls with benign nevi. However, when melanoma patients with or without metastases were compared, there were smaller differences, with only thrombin-antithrombin complex, plasmin-antiplasmin and D-dimer significantly higher in metastatic melanoma. These results indicate that in patients carrying a tumor endowed with high procoagulant activity in vitro, there is a laboratory picture of hypercoagulability with secondary hyperfibrinolysis in vivo. However, differences between patients with localized and metastatic tumors for markers of hypercoagulability are not striking, in spite of the fact that metastatic cells support greater coagulant activity than primary cells in vitro.

KW - activated factor VII

KW - hypercoagulability

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=0029992007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029992007&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(96)00006-0

DO - 10.1016/0049-3848(96)00006-0

M3 - Article

C2 - 8928092

AN - SCOPUS:0029992007

VL - 81

SP - 345

EP - 352

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -